Frazier Life Sciences Management, L.P.
Institutional manager — quarterly 13F holdings, Q ending 2026-03-31
Reported value
$3.89B
Q ending 2026-03-31
Prior quarter
$3.72B
Q ending 2025-12-31
Change
+4.4% QoQ · +77.6% YoY
Positions
38
reported holdings
Largest positions
All 38 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
| Holding | Ticker | Type | Value ▼ | Shares |
|---|---|---|---|---|
| Mirum Pharmaceuticals Inc | MIRM | Shares | $709.4M | 7.7M |
| Newamsterdam Pharma Company | Shares | $542.4M | 16.9M | |
| Erasca Inc | ERAS | Shares | $399.2M | 24.7M |
| Bridgebio Pharma Inc | BBIO | Shares | $256.1M | 3.4M |
| Arcutis Biotherapeutics Inc | ARQT | Shares | $232.6M | 9.9M |
| Mbx Biosciences Inc | MBX | Shares | $198.6M | 6.7M |
| Phathom Pharmaceuticals Inc | PHAT | Shares | $138.5M | 12.5M |
| Maze Therapeutics Inc | MAZE | Shares | $136.3M | 4.6M |
| Krystal Biotech Inc | KRYS | Shares | $124.3M | 481K |
| Trevi Therapeutics Inc | TRVI | Shares | $118.6M | 9.9M |
| Palvella Therapeutics Inc Ne | PVLA | Shares | $110.0M | 882K |
| Kalvista Pharmaceuticals Inc | 4XC1 | Shares | $99.9M | 5.0M |
| Disc Medicine Inc | IRON | Shares | $86.6M | 1.4M |
| Cytokinetics Inc | CYTK | Shares | $76.4M | 1.2M |
| Revolution Medicines Inc | RVMD | Shares | $65.7M | 676K |
| Dyne Therapeutics Inc | DYN | Shares | $57.2M | 3.2M |
| Savara Inc | SVRA | Shares | $53.1M | 9.7M |
| Tarsus Pharmaceuticals Inc | TARS | Shares | $51.1M | 729K |
| Vor Biopharma Inc | VOR | Shares | $45.4M | 2.5M |
| Agios Pharmaceuticals Inc | AGIO | Shares | $42.5M | 1.3M |
| Biocryst Pharmaceuticals Inc | BCRX | Shares | $38.2M | 4.0M |
| Zai Lab Ltd | ZLAB | Shares | $35.8M | 1.9M |
| Aura Biosciences Inc | AURA | Shares | $34.1M | 5.1M |
| Acadia Pharmaceuticals Inc | ACAD | Shares | $32.0M | 1.4M |
| Ascendis Pharma A/S | Shares | $30.5M | 133K | |
| Lexeo Therapeutics Inc | LXEO | Shares | $25.4M | 4.4M |
| Alkermes Plc | Shares | $24.8M | 701K | |
| Aclaris Therapeutics Inc | ACRS | Shares | $18.5M | 4.9M |
| Monte Rosa Therapeutics Inc | GLUE | Shares | $16.4M | 1.0M |
| Immunocore Hldgs Plc | IMCR | Shares | $14.6M | 485K |
| Mannkind Corp | MNKD | Shares | $14.5M | 5.9M |
| Valneva Se | VALN | Shares | $14.3M | 2.3M |
| Evolus Inc | EOLS | Shares | $10.8M | 2.6M |
| Newamsterdam Pharma Company | Shares | $10.0M | 500K | |
| Allogene Therapeutics Inc | ALLO | Shares | $9.3M | 3.8M |
| Autolus Therapeutics Ltd | AUTL | Shares | $6.1M | 4.4M |
| Ibio Inc | IBIO | Shares | $3.7M | 2.0M |
| Xilio Therapeutics Inc | XLO | Shares | $3.6M | 423K |
Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.